Abstract
Guidelines for assessments of connective tissue diseases in social jurisdiction and for insurance are not available in Germany. This article is a guideline reflecting published data, modern therapy and actual prognosis. In addition, help for interpretation and examples are given.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adult
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Connective Tissue Diseases / classification
-
Connective Tissue Diseases / diagnosis*
-
Connective Tissue Diseases / drug therapy
-
Critical Pathways*
-
Disability Evaluation*
-
Eligibility Determination / legislation & jurisprudence
-
Expert Testimony / legislation & jurisprudence*
-
Female
-
Germany
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects
-
Lupus Erythematosus, Systemic / classification
-
Lupus Erythematosus, Systemic / diagnosis
-
Lupus Erythematosus, Systemic / drug therapy
-
Male
-
Middle Aged
-
Patient Care Team / legislation & jurisprudence*
-
Prognosis
-
Rehabilitation, Vocational
-
Social Security / legislation & jurisprudence
-
Steroids
-
Work Capacity Evaluation
Substances
-
Anti-Inflammatory Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Immunosuppressive Agents
-
Steroids